Nanoform Finland
0.87
EUR
+16 %
3,527 following
NANOFH
First North Finland
Medical Equipment & Services
Health Care
Overview
Ownership
Investor consensus
Nanoform Finland is a medical technology company. The company specializes in the research and development of technical products used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. The customers consist of companies in the global pharmaceutical industry. Nanoform Finland mainly operates in the Nordic market and is headquartered in Helsinki.
Read moreMarket cap
74.41M EUR
Turnover
741.65K EUR
Revenue
2.57M
EBIT %
-874.71 %
P/E
-
Dividend yield-%
-
Financial calendar
21/8
2025
Interim report Q2'25
20/11
2025
Interim report Q3'25
26/2
2026
Annual report '25
All
Research
Webcasts
Press releases
ShowingAll content types
DEVELOPMENT OF NANOFORMED TRASTUZUMAB FOR SUBCUTANEOUS INJECTION TO BE PRESENTED AT DDF SUMMIT IN BERLIN
Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen
POSITIVE NANOFORM BIOLOGICS RESPIRATORY DATA TO BE PRESENTED AT DRUG DELIVERY AND FORMULATION SUMMIT
Nanoform Q1 2025 report: Deal mosaic emerge and commercial value clearly seen in our CESS® technology
INSIDE INFORMATION MADE PUBLIC: NANOFORM PARTNERS WITH TWO SPECIALIST HEALTHCARE INVESTORS TO DEVELOP AND COMMERCIALISE NANOENCORAFENIB
Invitation to Nanoform’s Q1 2025 Report Presentation
Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc
Resolutions of Nanoform Finland Plc's Annual General Meeting on April 15, 2025
Nanoform: Notice to the Annual General Meeting of NANOFORM FINLAND Plc

Nanoform, Audiocast with teleconference, Q4'24
Nanoform 2024 report: Deal discussions around product kernels intensify
Invitation to Nanoform's Q4 and FY 2024 Report Presentation
Nanoform Finland Plc - Managers' transactions - Antonio Da Silva
Nanoform Finland Plc - Manager's Transactions - Peter Hänninen
Nanoform Finland Plc - Manager's Transactions - Edward Hæggström
Nanoform Finland Plc - Manager's Transactions - Albert Hæggström
The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees
